Sam Slutsky
Stock Analyst at LifeSci Capital
(4.98)
# 65
Out of 4,581 analysts
613
Total ratings
54.8%
Success rate
49.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sam Slutsky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintained: Buy | $108 | $68.33 | +58.06% | 33 | Jul 28, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Buy | $56 | $35.69 | +56.91% | 42 | Jul 25, 2026 | |
| IFRX InflaRx | Maintained: Buy | $5 | $1.66 | +201.20% | 32 | Jul 25, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $22.51 | $8.46 | +166.12% | 8 | Jul 21, 2026 | |
| PVLA Palvella Therapeutics | Maintained: Buy | $225 | $140.11 | +60.59% | 24 | Jul 20, 2026 | |
| DBVT DBV Technologies | Rated: Buy | $46 → $45 | $13.44 | +234.82% | 13 | Jul 17, 2026 | |
| OKUR OnKure Therapeutics | Maintained: Buy | $16 | $3.97 | +303.02% | 13 | Jul 15, 2026 | |
| AVBP ArriVent BioPharma | Maintained: Buy | $42 | $29.31 | +43.30% | 26 | Jul 14, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $24 | $11.42 | +110.16% | 43 | Jul 13, 2026 | |
| SYRE Spyre Therapeutics | Rated: Buy | $103 → $119 | $95.67 | +24.39% | 52 | Jul 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $53 | $38.08 | +39.18% | 71 | Jul 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $170 | $123.04 | +38.17% | 35 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $100 | $21.00 | +376.19% | 1 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $0.7448 | +705.59% | 21 | Jun 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $28.48 | +58.01% | 6 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $52.70 | +13.85% | 37 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 | $87.00 | +43.68% | 20 | May 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $3.00 | +100.00% | 20 | May 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 | $12.85 | +335.80% | 4 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.95 | - | 28 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 | $39.33 | +39.84% | 50 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.16 | $1.38 | n/a | 11 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.71 | n/a | 23 | Aug 9, 2023 |
CG Oncology
Jul 28, 2026
Maintained: Buy
Price Target: $108
Current: $68.33
Upside: +58.06%
Celldex Therapeutics
Jul 25, 2026
Maintained: Buy
Price Target: $56
Current: $35.69
Upside: +56.91%
InflaRx
Jul 25, 2026
Maintained: Buy
Price Target: $5
Current: $1.66
Upside: +201.20%
Eupraxia Pharmaceuticals Inc.
Jul 21, 2026
Maintained: Buy
Price Target: $22.51
Current: $8.46
Upside: +166.12%
Palvella Therapeutics
Jul 20, 2026
Maintained: Buy
Price Target: $225
Current: $140.11
Upside: +60.59%
DBV Technologies
Jul 17, 2026
Rated: Buy
Price Target: $46 → $45
Current: $13.44
Upside: +234.82%
OnKure Therapeutics
Jul 15, 2026
Maintained: Buy
Price Target: $16
Current: $3.97
Upside: +303.02%
ArriVent BioPharma
Jul 14, 2026
Maintained: Buy
Price Target: $42
Current: $29.31
Upside: +43.30%
Olema Pharmaceuticals
Jul 13, 2026
Maintained: Buy
Price Target: $24
Current: $11.42
Upside: +110.16%
Spyre Therapeutics
Jul 11, 2026
Rated: Buy
Price Target: $103 → $119
Current: $95.67
Upside: +24.39%
Jul 11, 2026
Rated: Buy
Price Target: $45 → $53
Current: $38.08
Upside: +39.18%
Jun 30, 2026
Maintained: Buy
Price Target: $170
Current: $123.04
Upside: +38.17%
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $100
Current: $21.00
Upside: +376.19%
Jun 23, 2026
Maintained: Buy
Price Target: $6
Current: $0.7448
Upside: +705.59%
Jun 22, 2026
Maintained: Buy
Price Target: $45
Current: $28.48
Upside: +58.01%
Jun 11, 2026
Reiterated: Buy
Price Target: $60
Current: $52.70
Upside: +13.85%
May 23, 2026
Maintained: Buy
Price Target: $125
Current: $87.00
Upside: +43.68%
May 23, 2026
Maintained: Buy
Price Target: $6
Current: $3.00
Upside: +100.00%
May 16, 2026
Maintained: Buy
Price Target: $56
Current: $12.85
Upside: +335.80%
May 16, 2026
Maintained: Hold
Price Target: n/a
Current: $1.95
Upside: -
May 9, 2026
Maintained: Buy
Price Target: $55
Current: $39.33
Upside: +39.84%
Dec 14, 2023
Maintained: Hold
Price Target: $1.16
Current: $1.38
Upside: n/a
Aug 9, 2023
Rated: Hold
Price Target: n/a
Current: $5.71
Upside: n/a